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SPECIAL ARTICLE
They are also a major social and economic health problem in
terms of numbers of patients affected and the cost of treatment.
OSTEOPOROSIS A D BONE COMPOSITION
AND STRE GTH
Osteoporosis is a bone disorder in which total bone mass is
reduced without any change in the ratio of mineralised to non-
mineralised bone. This is in contrast to osteomalacia and
osteitis fibrosa, where mineralised bone is reduced and
replaced by osteoid or fibrous tissue. Osteoporosis and
osteomalacia can also be combined, and a definitive diagnosis
may only be made on bone biopsy. It is often impossible to
distinguish between these conditions using radiography or
bone densitometry. The term 'osteopenia' is best reserved for
the changes seen on radiograph or bone densitometry, as this
does not imply any particular underlying abnormality or cause.
Osteoporosis is a generalised process affecting the whole
skeleton, but some bones are more affected and more likely to
fracture than others. Bone loss is greater in trabecular bone,
which has four times the turnover of cortical bone, and bones
with a large proportion of trabecular bone, such as the
vertebrae and femoral neck, are more likely to become
osteoporotic and to fracture. Bone strength is determined by
bone mineral density (BMD), bone architecture and total bone
mass. Several methods have been developed for measuring
BMD, which accounts for 70 - 80% of the compression and
torsion strength of bone in vitro.' The compressive strength of
cancellous bone is proportional to the square of the density, so
that small changes in BMD are associated with relatively large
changes in bone strength. Reduction of bone density,
particularly of trabecular bone, is associated with a breakdown
of bone architecture and 'cross-bracing', which is another
important factor affecting bone strength. Because BMD is a
major determinant of bone strength and can be measured
accurately and reliably, the diagnosis of osteoporosis is now
based on the measurement of BMD.
However, the risk of a fragility fracture depends not only on
bone density and bone strength but also on several other·
factors including postural instability and propensity to falls,
impairment of muscle strength and neuromuscular co-
ordination and the risk of trauma and presence of
environmental hazards.' Many of these factors increase with
age and a fracture may be due as much to these and other
factors, such as hip geometry,' as to loss of bone density and
bone strength. Although BMD measurements are now used to
define osteoporosis, it is important to remember that BMD is






Osteoporosis is a condition of decreased bone mass and bone
density associated with an increase in fracture risk. Bone
mineral density (BMD) of the lumbar spine and femur can be
reliably measured by double-beam X-ray absorptiometry
(DEXA), which provides a measure of bone strength.
Reduction in BMD is a continuum and is associated with a
progressive increase in fracture risk. The diagnosis of
osteoporosis is based on BMD relative to that of healthy
young adults and criteria for diagnosis are arbritary. The
original 'normal' BMD data published by some
manufacturers were relatively high, leading to a relative over-
diagnosis of osteoporosis. Revised normative BMD values of
the spine and femur and revised criteria using degrees of
severity are proposed and may provide a better basis for
diagnosis and for the management of patients with
osteoporosis. The. indications for BMD measurement, the age
at which BMD is measured, and number of measurements,
depends upon the purpose of the measurement and how the
result will affect the management of each patient in clinical
practice.
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Osteoporosis is characterised by low bone mass and micro-
architectural deterioration of bone tissue with a consequent
increase in bone fragility and fracture risk. The lifetime risk of a
fracture of the spine, radius or femur due to osteoporosis in a
50-year-old Caucasian woman in the VI< or North America is
about 15%. The lifetime risk of any fracture due to osteoporosis
approaches 40% in women and 13% in men. The risk of
fracture is as great as that of having a heart attack and at least
four times greater than that of developing breast cancer.
Osteoporotic fractures are a major cause of morbidity and
mortality and of impaired well-being, especially in the elderly.
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Total bone mass and BMD increase throughout childhood and
adolescence, reach a peak around 20 years of age, and then
normally remain at a plateau until age 40 - 50. The peak bone
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mass in men is 10 - 50% higher than in women depending
upon the site of measurement, the difference being greater in
cortical bone and the appendicular skeleton.' From 40 years of
age there may be a slow loss of bone of between 0.5% and 1%
per year in men and in women until the menopause. After the
menopause there is marked acceleration in bone loss to
between 2% and 5% per year due to the fall in oestrogen
secretion by the ovaries. Accelerated bone loss continues for at
least the next 5 - 10 years and may then decline to reach a level
of about 0.5% per year by age 75. Bone loss in the early
postmenopausal years occurs mainly in cancellous bone and in
the axial skeleton, but by age 75 women have lost about the
same amount of bone from the axial and appendicular
skeleton. BMO is determined by the peak bone mass, the rate
of bone loss and the duration of loss (i.e. time since menopause
in postmenopausal women). At age 40 - 50 the BMD is
primarily a measure of peak bone mass and it provides a guide
to the possible development of osteoporosis and to the future
risk of fracture, although at this age only 2.5% of women will
have a BMD in the osteoporotic range. By age 70, however,
BMD is detennined equally by peak bone mass and by the
amount of bone lost since the menopause, and about 30% of
women will have BMD measurements in the osteoporotic
range. By 80 years of age 50% of women will have
osteoporosis.
BMD - GENETIC AND RACIAL FACTORS
Genetic and racial factors have an important effect on peak
bone mass, although the rate of bone loss does not appear to
differ significantly between black, Caucasian and Japanese
populations' Black women have a higher peak bone mass and
higher BMD than Caucasian women, even when adjusted for
weight and height, and have a lower incidence of osteoporotic
fractures.' Twin and family studies suggest that about half of
the differences in peak bone mass between different
individuals are due to genetic factors and about half to
environmental factors. The genetic factors may be related to
variability in the inheritance of the vitamin 0 receptor gene.'
With advancing age the effect of genetic and other factors that
detennine peak bone mass becomes less and factors that cause
bone loss, such as the menopause, have an increasing effect on
the development of osteoporosis.
METHODS OF MEASURI G BMD
Several techniques are available for the measurement of BMD
and bone mass, including dual energy X-ray absorptiometry
(OEXA), quantitative computed tomography (QCT) and
quantitative ultrasound (QUS). OEXA has become the method
of choice because of its high reproducibility, low radiation dose
(less than natural background) and ability to measure BMD at
both axial and appendicular sites. It is the only method by
which bone density can be measured in both the femur and the
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vertebrae. This is important because the best predictor of the
risk of fracture of any bone is the BMO at the site of
measurement,' and femoral fractures are by far the greatest
cause of morbidity and mortality. OEXA measurements of bone
density by skilled operators are very precise, with coefficients
of variation of 1% for the spine and 3% for the femur.
QCT has been used to measure the BMO of the lumbar spine
and peripheral bones such as the radius, ulna and tibia. It
permits separation of the BMO of trabecular and cortical bone
of the vertebrae and provides a volumetric measurement of
BMO. However, QCT of the spine requires larger doses of
radiation and is less precise than OEXA. QCT measurements of
the femur are not currently available and QCT has largely been
superseded by OEXA in the diagnosis of osteoporosis in most
centres. Peripheral QCT requires less radiation and permits
separate assessment of density and morphornetric changes of
peripheral bones·
Ultrasound (US) is a mechanical wave (not a radiation), and
its propagation in bone is very complex. The velocity and
attenuation of ultrasound is determined not only by the
mineral content but also by the structural properties of bone.
The speed or velocity of US (SOS) correlates with both the
density and the elasticity of bone, while broad-band ultrasound
attenuation (BUA) is principally dependent on the structural
characteristics of bone. A number of QUS devices have been
developed that measure both SOS and BUA, and the
manufacturers have derived different combined indices of bone
density and structure such as 'stiffness' (Lunar) and
'quantitative ultrasound index' (Hologic). The bone most
studied with QUS is the calcaneus. SOS and BUA
measurements of the calcaneus correlate with BMO
measurements of the calcaneus, femur and lumbar spine
(Table I),' but the correlation is not sufficiently close to allow
prediction of the BMD of the femur and vertebrae in individual
subjects. QUS measurements of the calcaneus nevertheless
appear to provide an indication of the risk of femoral neck
fracture that is independent and as good as that of BMD as
measured by OEXA. A decrease of 1 standard deviation (SO) of
either QUS or BMD is associated with an approximate
doubling of the risk of femoral neck fracture. Combining QUS
and BMO measurements may significantly improve the
prediction of fracture of the femur. ID However, QUS indices are
only indirectly correlated with BMO and do not permit the
diagnosis of osteoporosis according to World Health
Organisation (WHO) criteria, which are based on BMD. QUS is
Table I. Correlation coefficients between DEXA and QUS'
BMDbyDEXA Calcaneus SOS Calcaneus BUA
Calcaneus 0.756 0.617
Total body 0.650 0.574
Lumbar spine 0.467 0.447
Femoral neck 0.691 0.663
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also not currently applicable to the spine and does not provide
a prediction of the vertebral fracture risk. This is a
disadvantage as changes in the spine often precede those in the
femur. It is therefore unlikely that QUS will replace DEXA in
the assessment of fracture risk due to osteoporosis in
individual patients. QUS has nevertheless been widely
advocated as a screening procedure for the determination and
prediction of osteoporosis as QUS machines are simpler,
portable and less expensive than DEXA and no radiation is
involved.
BMD, FRACTURE RISK AND DIAGNOSIS OF
OSTEOPOROSIS
OEXA measurements of BMD are expressed as absolute values
(g/cm') based on bone mineral content (BMC) divided by the
particular area of bone scanned. BMD measurements follow a
Gaussian distribution and can be defined in terms of the mean
and SD. The SO does not change with age, and the 'normal'
range of BMD can be specified either as that applicable to a
particular age (Z-score) or as that of healthy young adults (T-
score). The risk of fracture is directly related to the absolute
BMD irrespective of age, and the diagnosis of osteoporosis is
based on the BMD relative to that of healthy young adults or T-
score. ormative data are most commonly given for females as
osteoporosis is much more common in women. Men have a
higher peak bone mass, lose bone less rapidly, and have a
lower risk of fracture for any given BMD than women.
Different normal ranges and different criteria for the diagnosis
of osteoporosis and assessment of fracture risk are therefore
required for menU
The risk of a fragility fracture progressively increases with
decrease in BMD such that a decrease of 1 SD corresponds to
an approximately 1.5 increase in risk of vertebral fracture and a
threefold increase in risk of femoral fracture.] BMD and risk of
fracture are a continuum like blood pressure and blood
cholesterol. The relation between BMD and the risk of a
fragility fracture is at least as close as that between blood
pressure and risk of stroke, and is closer than that between
blood cholesterol and the risk of myocardial infarction. BMD
measurements in women with a femoral and/or vertebral
fracture and in those without fractures, however, overlap, and
there is no specific threshold below which fractures suddenly
become more frequent. The term 'fracture threshold' is
therefore a misnomer and is misleading. The diagnosis of
osteoporosis in terms of BMD measurements depend entirely
upon the normative data and the diagnostic criteria chosen.
Osteoporosis is not a specific disease entity but rather a state of
decreased bone density and bone mass relative to that of
healthy young adults."
In 1994 the WHO published a report entitled Assessment of
Frachlre Risk and its Application to Screening for Postmenopausal
Osteoporosis," while the National Osteoporosis Foundation of
South Africa has published 'Guidelines for the early detection of
Table IT. Osteoporosis diagnostic categories13
Normal BMD* or BMC* within 1 SD of ref. meant
Low bone mass BMD* or BMC* more than 1 SD below ,ref.
meant but less than 2.5 SD below this
value
Osteoporosis BMD or BMC* 2. 5 SD or more below ref.
meant
Severe osteoporosis BMD* or BMC* more than 2.5 SD below
meant in the presence of one or,more
fragility fractures
•At anyone site (spine, hip or radius).
tMean and range of healthy young adult females.
osteoporosis and prediction offracture risk' (Table IT)." In the WHO
report the value of 2.5 SD below the mean of young healthy
adult women at any site (spine, hip or radius) was chosen as
the cut-off because this value identifies 30% of all
postmenopausal women as having osteoporosis, which is
approximately equivalent to the lifetime risk of fracture at any
of these sites. This does not mean, however, that every woman
with a BMD of 2.5 SD or less will necessarily have a fragility
fracture in her lifetime, but only that this cut-off delineares a
similar proportion of about 30% of the total population.
Women with a BMD of more than 1 SD below but less than
2.5 SD below the young adult mean are categorised as having a
'low bone mass'. The occurrence of a fragility fracture greatly
increases the risk of subsequent fractures over and above the
risk associated with BMD alone. Women with a BMD of 2.5 SD
below the mean who have had a fracture are categorised as
having 'severe osteoporosis'. The publication of the WHO
criteria was a major advance, but these diagnostic categories
have some disadvantages in clinical practice. Patients who
happen to fall below the arbitrary 'fracture threshold' of 2.5 SD
below the mean are diagnosed as having osteoporosis, and
such patients sometimes regard themselves as having acquired
a serious or even life-threatening condition. Patients who are
diagnosed as having 'low bone mass' may similarly take fright.
In contrast, those above this arbitrary limit may regard
themselves as not being at risk of fracture and not needing any
preventive measures or treatment. A proposed classification
according to degree of severity using the terms mild, moderate
and severe (Table ill) helps to overcome this problem and it
should be explained to patients that bone density, fracture risk
and the diagnosis of osteoporosis are a matter of degree.
NORMAL REFERENCE POPULATIONS
The values of BMD measured by different DEXA instruments
vary depending upon the allowance made for bone fat and
other factors. The 'normal' reference ranges also differ
depending on the selection and size of the different 'normal'
populations chosen by different investigators. Furthermore, the
charts for 'normal' populations depend on the mathematical
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'At anyone site at which BMD is measured.
tMean and range of healthy yOWlg adult females.
Table ID. Osteoporosis proposed diagnostic categories according






BMD of not more than 1 SO below re£.
meant at all sites measured
BMD" of 1 SO or more but greater than
2 SO below ref. meant
BMD" of 2 SO or more but greater than
3 SD below ref. meant
BMD" of 3 SO or more but greater than
4 SO below ref. meant
BMD* of 4 SO or more below ref. meant
ar BMD of 2 SO or more below meant
with one or more previous or existing
fragility fractures
found that three out of four women were misdiagnosed as
having osteoporosis using original Hologic QOR reference
data. Faulkner et al. I; proposed that normal means and ranges
should be redefined for all densitometers using the NHANES
ill data to avoid discrepancies. They also suggested that the
definition of osteoporosis should be revised from 2.5 SD to
2 SD below the mean of young normal subjects at the femoral
neck, but stressed that these proposals should be confirmed
through the establishment of consistent normative data.
Manufacturers are now beginning to publish different 'normal'
ranges and different criteria for the diagnosis of osteoporosis
based on the NHANES ID data. Proposed criteria for the
diagnosis of osteoporosis according to degree of severity, as
based on redefined absolute values of BMO derived from
NHANES ill database and the recommendations of Faulkner et



























































Table V. Osteoporosis diagnostic criteria of lumbar spine Ll - L4
based on redefined BMD values·"
Table VI. Osteoporosis diagnostic categories of femoral neck
based on redefined BMD values·'"
I DICATIO S FOR BMD MEASUREME T
The WHO Study Group and the ational Osteoporosis
Foundation of South Africa have published indications for
bone densitometry. It is generally agreed that population
screening is not justified on an epidemiological or cost-benefit
basis. The use of BMD measurement is therefore restricted to
the management of individual patients and the selective
screening of high-risk groups. A simplified list of indicatiOns
based on the guidelines of the ational Osteoporosis
Foundation are given in Table VII. There are other factors that
need to be considered with regard to bone densitometry and
the diagnosis of osteoporosis in clinical practice.
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methods used to calculate the means and ranges for the
different age groups. The definitions of osteoporosis based on
mean and SD of BMD were introduced to overcome the
problem of differences in absolute measurements, but further
investigations have revealed significant differences in the mean
and SO measurements published by different manufacturers.
Faulkner et al. 15 investigated the discrepancies in normative
data between Lunar and Hologic DEXA systems. They
measured the BMD of the lumbar spine and femur with both
systems on the same day in 83 women aged 18 - 86 years, with
an average age of 60 years. There were no clinically significant
differences in the T-scores of the lumbar vertebrae, but on
linear regression analysis there was a systematic difference of
0.9 SO in the T-scores of the femoral neck. Using the WHO
definition of 2.5 SD below the mean of young adults, they
found that 52% of women would be diagnosed as having
osteoporosis of the femoral neck using the Hologic scanner but
only 23% using the Lunar scanner. They then recalculated the
means and SOs of the BMD of the femoral neck of young
normal females for both the Hologic and Lunar systems using
the NHANES ID data,!- and the revised values were then
equivalent (Table IV). The prevalence of osteoporosis in the
series with revised values was then approximately 30%, with
both systems using WHO criteria. Simmons et al. 17 examined
the problem in a group of 2 500 women aged 20 - 90 years and
Table IV. Reported and redefined BMD values of lumbar spine
and femora) neck"
BMD" Hologic Lunarm3 (g/cm2) Age Mean SD Age Mean SD
Ll- L4 spine 30 1.047 0.11 20-45 1.180 0.12
Femur neck
Reported 22 0.895 0.10 20 -45 0.980 0.12
Redefined 20-29 0.85 0.11 20 - 29 1.00 0.11
'Healthy young adult females.
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Table VII. Indications for bone densitometry
1. Past or present fragility fracture or any fracture in
postmenopausal women
2. 'Osteopenia' or 'osteoporosis' suspected on radiograph
3. Medical/surgical disorders known to cause osteoporosis
4. Treatment with corticosteroids (> 5 g prednisolone daily or
equivalent for> 6 months), cytotoxic or other drugs known
to affect bone adversely
5. Assessment of peri- or postmenopausal women for possible
HRT
6. Premature menopause and any amenorrhoea lasting longer
than 6 months in women less than 45 years of age
7. Post-bilateral oophorectomy or post-hysterectomy in women
45 years of age or less with menopausal symptoms
8. Presence of one or more strong risk factors including family
history of osteoporosis or fragility fracture
9. Monitoring response to treatment of osteoporosis
1. The predictive value of clinical risk factors to identify
individual patients with osteoporosis is low. More than half of
the individuals without risk factors will develop osteoporosis
and many with risk factors ",ill have normal BMD.
2. Measurements of BMD are only justified when they affect
patient management. If women are already on hormone
replacement therapy (HRT) and are not concerned about
osteoporosis or the risk of fracture then measurement of BMD
serves little purpose.
3. Assuming that facilities are available and that cost is no
consideration, then individuals are entitled to request BMD
measurement in order that they may be informed about their
BMD and future risk of fracture. This may help to allay
unwarranted fears and enable individuals to decide whether or
not to embark on therapy.
4. Repeat BMD measurements are essential in order to
monitor response to treatment. In a personally observed series
of 100 postmenopausal women on HRT who had repeat DEXA
measurements approximately annually, 60% showed a
significant increase in BMD, 30% were within the range of
measurement error and were regarded as unchanged, but 10%
of women showed a significant fall in BMD of either the femur
or spine in spite of therapy. Such patients require investigation
and additional treatment to prevent further bone loss. It is
therefore recommended that all patients being treated for
osteoporosis should ideally have BMD measurements annually,
at least initially. The intervals between measurements can be
extended gradually in patients who have a progressive increase
in BMD or whose BMD measurements are in the 'low bone
mass' range. Most patients are keen to know how they are
progressing and repeat measurements are often of considerable
value in ensuring continuation of therapy.
5. The absence of facilities for bone densitometry is no bar to
the prophylaxis or treatment of osteoporosis, even though the
diagnosis may be presumptive and less certain. Ideally all
women should commence HRT at the menopause to prevent
bone loss and osteoporosis. Bone density may be increased by
appropriate therapy. It may, however, not be possible to restore
normal bone architecture completely in patients who have
already developed osteoporosis.
WHEN TO MEASURE BMD
The age at which BMD should be measured in the absence of
any special risk factors such as premature menopause depends
upon the clinical situation and the purpose of the
measurement. The peak bone mass at the menopause is the
best guide to the future development of osteoporosis although
the prevalence of osteoporosis at this time is low. If the aim is
to provide an estimate of future risk with a view to starting
preventive therapy, then BMD is best measured at the
menopause. Treatment can then be started immediately and
bone loss and osteoporosis may be prevented. However if the
aim is to diagnose osteoporosis, BMD is best measured
between 60 and 65 years of age. By this time women will have
passed through the acute phase of postmenopausal bone loss
but there is still sufficient time to initiate therapy and to
prevent vertebral and, more importantly, hip fractures that
occur when women are in their 70s and 80s. It is probably
never too late to measure BMD or to start treatment. Even if
treatment for osteoporosis is only started at age 70 the
incidence of hip fracture is still Significantly reduced. IS In
practice the timing of BMD measurement is often determined
by the age at which the patient first presents and her wishes
regarding treatment.
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